Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) released its earnings results on Monday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
Guided Therapeutics Stock Down 8.3%
Shares of GTHP stock traded down $0.01 during trading hours on Monday, hitting $0.11. 3,200 shares of the company’s stock traded hands, compared to its average volume of 27,412. The stock’s fifty day simple moving average is $0.19 and its two-hundred day simple moving average is $0.25. Guided Therapeutics has a 12-month low of $0.10 and a 12-month high of $0.54. The stock has a market cap of $10.80 million, a price-to-earnings ratio of -2.75 and a beta of 0.78.
Guided Therapeutics Company Profile
Guided Therapeutics is a medical technology company focused on developing tools for the detection of cervical disease. Its principal product is the LuViva Advanced Cervical Scan, a non-invasive device designed to assess cervical tissue for signs associated with precancerous changes and cancer. LuViva uses optical technologies to examine tissue and provide information that can support cervical disease evaluation. The company’s work centers on offering an alternative to diagnostic approaches that rely on collecting and analyzing tissue samples.
Read More
- Five stocks we like better than Guided Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
